Filing Flows › Co-Diagnostics (CODX) › Takeover & LBO
Is Co-Diagnostics (CODX) a takeover target?
A leveraged buyout does not work for Co-Diagnostics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-10-23): Milbank, Paul Weiss Among Firms Advising on EQT’s $12B Take-Private of Diagnostics Company.
Why a leveraged buyout does not fit
The buyout model needs Co-Diagnostics' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-10-23 · news · Milbank, Paul Weiss Among Firms Advising on EQT’s $12B Take-Private of Diagnostics Company
- 2026-10-22 · news · EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private
- 2026-10-21 · news · Buyout firm EQT acquires German diagnostics group in €10.8bn deal
Co-Diagnostics' latest quarter
Co-Diagnostics, Q2 2026: revenue $166K (+2% year over year), net loss $6.3M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
Is Co-Diagnostics being acquired?
The latest signal on file is from 2026-10-23: Milbank, Paul Weiss Among Firms Advising on EQT’s $12B Take-Private of Diagnostics Company. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Co-Diagnostics?
A leveraged buyout does not work for Co-Diagnostics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.